Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Thyroid Gland Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Site
Head and Neck Neoplasm
Neck Neoplasm
Thyroid Gland Neoplasm

Subtype

Thyroid Gland Neoplasm

CI-CAN-00001600Explore in graph →

Non-malignant189 active trials10 approved drugs63 evidence items

NCIt: C3414
MeSH: D013964

Overview
Statistics
Survival
Genomics6
Variants & evidence63
Drugs18
Trials891
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (126)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 101–125 of 126 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants.
· Oncotarget · 2016 · PMID 27086918 · validated civic_curation pubmed
Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer.
· J Clin Oncol · 2010 · PMID 20368568 · validated civic_curation pubmed
Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy.
· Endocr Relat Cancer · 2014 · PMID 25121551 · validated civic_curation pubmed
The association of the BRAF(V600E) mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis.
· Cancer · 2012 · PMID 21882184 · validated civic_curation pubmed
NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States.
· Cancer · 2016 · PMID 26784937 · validated civic_curation pubmed
Re: "A Case Report of Poor Response to Selpercatinib in the Presence of a 632_633 RET Deletion" by Wijewardene et al.
· Thyroid · 2023 · PMID 37376747 · validated civic_curation pubmed
Genotype-phenotype correlation of patients with multiple endocrine neoplasia type 2 in Japan.
· Jpn J Clin Oncol · 1998 · PMID 9839497 · validated civic_curation pubmed

Showing 101–125 of 126 publications

← Previous
1
…
4
5
6
Next →

Telomerase in differentiated thyroid cancer: promoter mutations, expression and localization.

· Mol Cell Endocrinol · 2015 · PMID 25448848 · validated civic_curation pubmed

Response and acquired resistance to everolimus in anaplastic thyroid cancer.

· N Engl J Med · 2014 · PMID 25295501 · validated civic_curation pubmed

Extended Antitumor Response of a BRAF V600E Papillary Thyroid Carcinoma to Vemurafenib.

· Case Rep Oncol · 2014 · PMID 24987354 · validated civic_curation pubmed

Selective RET kinase inhibition for patients with RET-altered cancers.

· Ann Oncol · 2018 · PMID 29912274 · validated civic_curation pubmed

RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.

· J Thorac Oncol · 2020 · PMID 31988000 · validated civic_curation pubmed

NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.

· J Clin Invest · 2021 · PMID 34237031 · validated civic_curation pubmed

Follicular thyroid carcinoma with NRAS Q61K and GNAS R201H mutations that had a good (131)I treatment response.

· Endocrinol Diabetes Metab Case Rep · 2016 · PMID 26788326 · validated civic_curation pubmed

Remarkable Response to Crizotinib in Woman With Anaplastic Lymphoma Kinase-Rearranged Anaplastic Thyroid Carcinoma.

· J Clin Oncol · 2015 · PMID 24687827 · validated civic_curation pubmed

Application of genomics to identify therapeutic targets in recurrent pediatric papillary thyroid carcinoma.

· Cold Spring Harb Mol Case Stud · 2018 · PMID 29610391 · validated civic_curation pubmed

An impressive response with larotrectinib in a patient with a papillary thyroid carcinoma harboring an SQSTM1-NTRK1 fusion.

· Eur J Endocrinol · 2022 · PMID 35118995 · validated civic_curation pubmed

Clinicopathologic and molecular characterization of NTRK-rearranged thyroid carcinoma (NRTC).

· Mod Pathol · 2020 · PMID 32457407 · validated civic_curation pubmed

MEN1 mutations in Hürthle cell (oncocytic) thyroid carcinoma.

· J Clin Endocrinol Metab · 2015 · PMID 25625803 · validated civic_curation pubmed

RET mutation heterogeneity in primary advanced medullary thyroid cancers and their metastases.

· Oncotarget · 2018 · PMID 29515777 · validated civic_curation pubmed

NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls.

· Mod Pathol · 2020 · PMID 31375766 · validated civic_curation pubmed

NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.

· Cancer Discov · 2015 · PMID 26359368 · validated civic_curation pubmed

Anti-tumor activity of motesanib in a medullary thyroid cancer model.

· J Endocrinol Invest · 2012 · PMID 21422803 · validated civic_curation pubmed

AZD1480 blocks growth and tumorigenesis of RET- activated thyroid cancer cell lines.

· PLoS One · 2012 · PMID 23056499 · validated civic_curation pubmed

Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.

· Cancer Res · 2009 · PMID 19706758 · validated civic_curation pubmed